Mucha Slawomir A, Kunert-Radek Jolanta, Pomorski Lech
Department of Clinical Endocrinology, Chair of Endocrinology, Medical University, Lodz.
Endokrynol Pol. 2006 Jul-Aug;57(4):452-5.
Medullary thyroid carcinoma (MTC) is usually more advanced at presentation than differentiated thyroid cancers and often has distant metastases. The primary treatment of MTC is total thyroidectomy and regional lymph node dissection. The efficacy of these procedures has been limited by the aggressiveness of the disease and metastatic spread at the time of surgery. Persistently elevated levels of calcitonin (CT) and carcinoembryonic antigen (CEA) or their increase postoperatively are indicative for residual or recurrent disease. Conventional imaging methods such as ultrasonography, computed tomography, magnetic resonance imaging and MIBI scintigraphy usually fail to find the source of calcitonin. Better imaging properties have been shown by DMSA scintigraphy, somatostatin receptor scintigraphy or by positron emission tomography (PET). The aim of the study was to evaluate the diagnostic accuracy of PET for the localisation of occult MTC in patients after surgery with increased concentrations of CT, in whom conventional imaging procedures have not been successful.
The PET investigation using (18)F-fluoro- 2-deoxy-D-glucose combined with computed tomography ((18)FDG-PET/CT) was performed at the Department of Nuclear Medicine (Oncology Centre in Bydgoszcz) between January and October 2004. In five patients with postoperative calcitonin ranging from 164 to > 2000 ng/l (normal < 10 ng/l) no tumour lesions were found using other imaging methods.
In four of five cases, responsible lesions with a higher metabolism of FDG, indicating MTC tissue (remnants or metastases), were localised. In one patient no focus of FDG accumulation was found despite high CT concentration. PET detected tumour manifestations in the neck and the mediastinum in two patients, in the lung and the left adrenal gland in one case and in the neck and the liver in another patient. As a result of surgery for the removal of a residual tumour or metastases the accuracy of diagnosis was confirmed by histopathology in all four cases and a decrease in CT and CEA levels was observed in 3/4 cases. The metabolic imaging findings by PET/CT ensured that the surgery on these patients was successful.
For the detection of occult residual or metastatic MTC lesions, (18)FDG-PET is a valuable procedure in imaging diagnostics.
甲状腺髓样癌(MTC)在就诊时通常比分化型甲状腺癌病情更严重,且常发生远处转移。MTC的主要治疗方法是全甲状腺切除术和区域淋巴结清扫术。这些手术的疗效受到疾病侵袭性和手术时转移扩散的限制。降钙素(CT)和癌胚抗原(CEA)持续升高或术后升高提示存在残留或复发性疾病。传统的成像方法,如超声、计算机断层扫描、磁共振成像和MIBI闪烁显像通常无法找到降钙素的来源。二巯基丁二酸(DMSA)闪烁显像、生长抑素受体闪烁显像或正电子发射断层扫描(PET)已显示出更好的成像特性。本研究的目的是评估PET对术后CT浓度升高且传统成像程序未成功的患者隐匿性MTC定位的诊断准确性。
2004年1月至10月期间,在比得哥什肿瘤中心核医学科进行了使用(18)F-氟-2-脱氧-D-葡萄糖联合计算机断层扫描((18)FDG-PET/CT)的PET检查。5例术后降钙素水平在164至>2000 ng/l(正常<10 ng/l)之间的患者,使用其他成像方法未发现肿瘤病变。
5例患者中有4例定位到了具有较高FDG代谢的责任病变,提示为MTC组织(残留或转移灶)。1例患者尽管CT浓度很高,但未发现FDG聚集灶。PET在2例患者的颈部和纵隔检测到肿瘤表现,1例在肺部和左肾上腺,另1例在颈部和肝脏。由于手术切除了残留肿瘤或转移灶,所有4例患者的组织病理学均证实了诊断准确性,3/4的病例观察到CT和CEA水平下降。PET/CT的代谢成像结果确保了这些患者手术成功。
对于隐匿性残留或转移性MTC病变的检测,(18)FDG-PET在影像诊断中是一种有价值的检查方法。